logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Phase 3 Study Of Torisel In Combination With Bevacizumab Fails

Pfizer Inc (PFE) Friday announced that its Phase 3 INTORACT trial , evaluating the combination of bevacizumab plus TORISEL compared with bevacizumab plus interferon-alfa-2a, or IFN-a-2a, did not meet its primary endpoint of superiority in extending progression free survival , or PFS, in the study population.

The company stated that the Phase 3 trial was carried out in the first-line treatment of patients with advanced renal cell carcinoma, or RCC, across risk groups.

The company further stated that the combination of bevacizumab and IFN-a-2a is approved as first-line treatment for advanced RCC and clinical supplies of both of these drugs in this trial were provided through an agreement with Roche.

"This trial advances our knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "Additional analyses will be performed to help us understand this result. The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cisco Systems Inc. (CSCO), the world's largest computer networking gear maker, is accelerating its ability to deliver on growth opportunities, aggressively driving its cloud business, and delivering continued strength in its deferred product revenue, as we sell more of its portfolio in software and cloud models. In fiscal 2016, the company sees a 25% increase in major new product introductions. Sanofi (SNYNF, SNY) reported that its fourth-quarter net income attributable to equity holders decreased to 334 million euros from 1.34 billion euros, last year. Earnings per share was 0.26 euros compared to 1.02 euros. Earnings per share excluding the held for exchange Animal Health Business was 0.41... Tour operator TUI Group reported narrower EBITA loss in its first quarter with increased turnover, driven by strong performances in Northern Region and Cruises. Further, the company said its current trading for Winter 2015/2016 and Summer 2016 remains in line with its expectations. Looking ahead, TUI reiterated its outlook to deliver underlying EBITA growth of at least 10 percent in fiscal 2016.
comments powered by Disqus
RELATED NEWS
Trade PFE now with 
Follow RTT